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INTRODUCTION
Trypanosomatid protozoan parasites comprise genus
of Trypanosoma and Leishmania that cause neglected
tropical diseases. Leishmaniasis is seen frequently in 88
countries on four continents (Southeast Asia, Africa,
South America including mostly Brazil and Mediterra-
nean countries) and cause 1.6 million new cases annu-
ally1. Leishmaniasis is transmitted by infected female
sandflies to the vertebrate hosts and reproduces within
macrophages. Three clinical forms of leishmaniasis are:
cutaneous leishmaniasis (L. major, L. tropica and L.
mexicana); visceral leishmaniasis (L. donovani and L.
infantum) and mucocutaneous leishmaniasis (L.
braziliensis) are seen in human hosts2, 3.
Like other trypanosomatids, L. mexicana has no genes
for glutathione reductase (GR), thioredoxin reductase
(TrxR), catalase and selenocysteine-containing glu-
tathione peroxidase which are responsible for intracellu-
lar thiol redox homeostasis in mammals4. Parasites
have dithiol trypanothione [T(SH)2] and trypanothione
reductase (TR) in their redox metabolisms which are com-
mon for all trypanosomatids but absent in hosts5, 6.
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ABSTRACT
Background & objectives: Trypanothione reductase (TR) is a member of FAD-dependent NADPH oxidoreductase
protein family and it is a key enzyme which connects the NADPH and the thiol-based redox system. Inhibition
studies indicate that TR is an essential enzyme for parasite survival. Therefore, it is an attractive target enzyme for
novel drug candidates. There is no structural model for TR of Leishmania mexicana (LmTR) in the protein databases.
In this work, 3D structure of TR from L. mexicana was identified by template-based in silico homology modeling
method, resultant model was validated, structurally analyzed and possible ligand binding pockets were identified.
Methods: For computational molecular modeling study, firstly, template was identified by BLAST search against
PDB database. Multiple alignments were achieved by ClustalW2.  Molecular modeling of LmTR was done and
possible drug targeting sites were identified. Refinement of the model was done by performing local energy
minimization for backbone, hydrogen and side chains. Model was validated by web-based servers.
Results: A reliable 3D model for TR from L. mexicana was modeled by using L. infantum trypanothione reductase
(LiTR) as a template. RMSD results according to C-alpha, visible atoms and backbone were 0.809 Å, 0.732 Å and
0.728 Å respectively. Ramachandran plot indicates that model shows an acceptable stereochemistry.
Conclusion: Modeled structure of LmTR shows high similarity with LiTR based on overall structural features like
domains and folding patterns. Predicted structure will provide a source for the further docking studies of various
peptide-based inhibitors.
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Trypanosomatids are exposed to reactive oxygen (super-
oxide anion radical, hydrogen peroxide, peroxynitrite and
the hydroxyl radical) and nitrogen molecules that are origi-
nated from parasite itself as by-product of aerobic me-
tabolism or from the host macrophage defense system5, 7.
Elimination of the various hydroperoxidases occurs via
an electron transfer cascade which contains the enzymes
of trypanothione, trypanothione reductase, tryparedoxin
and tryparedoxin peroxidase6. These low molecular mass
thiols and redox enzymes protect enzymes from reactive
derivatives and facilitate adaptation to various metabolic
and environmental conditions5.
One of the low molecular mass thiol compound is
trypanothione [T(SH)2] which is synthesized from two
GSH and one spermidine molecule by glutathionyl sper-
midine/trypanothione synthetase (TryS) enzyme, an ATP
driven reaction4. Trypanothione reductase uses NADH
as an electron donor for the reduction of trypanothione
disulfide to trypanothione. Because of lacking of GR and
TrxR in trypanosomatids, TR is a key enzyme which con-
nects the NADPH and the thiol-based redox system5.
Trypanothione reductase knock out studies on L. donovani
and L. major show decreased capacity to survive inside 39 Mutlu: Homology modeling of trypanothione reductase
host macrophages8, 9. Conditional knock out studies on
T. brucei resulted with growth arrest, loss of viability and
virulence10. Inhibition studies showed that numerous com-
pounds inhibit trypanosomatid TR but not inhibit host
GR11–14. These works indicate that TR is an essential en-
zyme for parasite survival6. So, TR is an attractive target
enzyme for novel drug candidates because of the absence
of trypanothione redox system in mammals15–17.
Trypanothione reductase is a member of FAD-depen-
dent NADPH oxidoreductase protein family and shares
close structural similarities with GR, lipoamide dehydro-
genase and eukaryotic TrxRs5. It has a mass of 52 kDa,
comprises of a FAD and NADPH binding, central and
interface domains and has two active sites. Structural fea-
tures of TR from trypanosomatids and crystal structures of
TR from T. cruzi18,19, Crithidia fasciculata20 and L.
infantum21 were solved. However, there is no 3D model for
TR of L. mexicana (LmTR) in the protein databases. In this
work, in silico homology modeling approach was used to
determine 3D model of TR from L. mexicana, model was
validated by web-based tools, structure was analyzed and
possible drug target pockets were identified.
MATERIAL & METHODS
Template selection and multiple sequence alignment
The National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov) database was used to ob-
tain amino acid sequence of the target TR from L.
mexicana (LmTR) (MHOM/GT/2001/U1103) with the
accession number of CBZ23392. Template identification
was done by NCBI BLAST tool and two types of BLAST
(Basic Local Alignment Search Tool), protein-protein
BLAST and PSI-BLAST (Position Specific Iterated-
BLAST) were performed for template selection
against database Protein Data Bank (PDB) proteins.
Homolog structure having the best score was selected as
a template protein after comparative searching.
Template protein PDB file and amino acid sequence
in FASTA format was downloaded from the PDB
(http://www.rcsb.org/pdb/home/home.do). Multiple se-
quence alignment was performed by both Molsoft and
ClustalW222 from the European Bioinformatics Institute.
Homology model development and validation
A 3D model for the LmTR enzyme was built by
Molsoft ICM. Knowledge from the target sequence, align-
ment and 3D structure of the template protein which was
obtained from the PDB was used to construct the model.
Refinement of the obtained model was achieved by per-
forming local energy minimization for backbone, hydro-
gen and side chains. Secondary structure of the protein
was estimated by web-based program SOPMA23.
Validation of the resultant protein model was achieved
by checking stereochemistry, energy profile and residue
environment. RAMPAGE Server24 was used to check
stereochemistry of the model. Model quality was
analyzed by ProSA25 and Protein Structure Validation
Suite—PSVS 1.3 (http://psvs-1_4-dev.nesg.org). Statis-
tics of non-bonding interactions was performed by
ERRAT Server v.2.026. Physical and chemical parameters
for the modeled protein (molecular weight, theoretical pI,
amino acid composition, extinction coefficient, aliphatic
index and grand average of hydropathicity) were per-
formed by ProtParam tool27.
Ligand binding site identification
Possible ligand binding sites/pockets on the 3D
structure of protein were identified by Molsoft-ICM
PocketFinder, web-based servers of CASTp-computer
atlas of surface topography of proteins28 and GHECOM
1.0: Grid-based HECOMi finder29.
RESULTS & DISCUSSION
Template selection and multiple sequence alignment
BLAST searching of the TR from L. mexicana
(LmTR) was performed against PDB proteins. The four
top scores were from L. infantum (PDB number: 2JK6,
Max score: 932, Identity: 91%, E-value: 0); C. fasciculata
(PDB number: 1FEA, Max score: 832, Identity: 80%, E-
value: 0); T. cruzi (PDB number: 1NDA, Max score: 686,
Identity: 68%, E-value: 0); and T. brucei (PDB number:
2WBA, Max score: 686, Identity: 66%, E-value: 0).
Evolutionary tree showed these proteins have closely
related amino acid compositions. Sequence identity above
50% is ideal for structure-based drug design and target
assessment, site directed mutagenesis and assignment of
protein function30. Therefore, according to the identity,
max score and E-value, the closest enzyme sequence was
from L. infantum (PDB 2JK6) that was selected as a tem-
plate for in silico homology modeling. Figure 1 shows
multiple sequence alignments of the TR from L. mexicana
(LmTR), L. infantum (LiTR), C. fasciculata (CfTR), T.
brucei (TbTR) and T. cruzi (TcTR) enzymes based on
evolutionary tree. Multiple sequence alignment results
showed that identity between LmTR and LiTR is 90%,
CfTR is 80%, TcTR is 67%, and TbTR is 65% which
were nearly same as  that of BLAST search results.
Homology model development and validation
Trypanothione reductase from L. mexicana was mod- J Vector Borne Dis 50, March 2013 40
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eled by using the parameters of the template structure and
target amino acid sequence. Number of models were
genereted and then RMSD (root mean square deviation)
values between target and template structures were calcu-
lated based on C-alpha, visible atoms and backbone traces.
Lower RMSD indicates stereochemically similar template
and target structures, and the model with the best RMSD
score was selected for further model validation study. Root
mean square deviation results according to C-alpha, vis-
ible atoms and backbone were 0.809 Å, 0.732 Å and 0.728
Å respectively (Fig. 2). Selected model was checked for
stereochemistry, energy profiles, potential errors, non-
bonding interactions and some physical and chemical prop-
erties. ProtParam results show that the protein model is
about 53.2 kDa, pI is 5.58, has 60 negatively and 49 posi-
tively charged residues, extinction coefficient is 46,465,
aliphatic index is 85.58 and grand average of
hydropathicity is –0.095. According to the RAMPAGE24
results, 96.7% of residues (472) are in favoured region,
3.3% (16) of them are in allowed and no residue in the out-
lier region in Ramachandran plot. ERRAT was used to
predict non-bonding interactions by examining the statis-
tics of pair wise atomic interactions (CC, CN, CO, NN, NO,
and OO). As a result, 93.562 as overall quality factor was
obtained which means the model has good resolution struc-
ture and only four residues were indicated as rejected26.
ProSA calculates overall protein quality based on the scores
of all experimentally determined protein chains available
in PDB. The program gives a z-score and a plot of the resi-
due energies25. Z-score of LmTR was –10.94 which indi-
cates that the model was within the range of the typically
found proteins of similar size and the structure is non-prob-
lematic according to the energy plot. Protein structure
validation suite (PSVS 1.3) was performed for analyzing
overall model quality based on the global quality scores of
four different structure validation programs (Verify3D,
ProsaII, Procheck and MolProbity). All quality check re-
sults show the model is close to the native form and the
environment profile of the structure is good. PDB file of
the resultant model has been deposited in the protein model
database (http://mi.caspur.it/PMDB) with the ID number
of PM0078340.
Fig. 2: (a) Superimposition of the target (LmTR) and the template
(LiTR) enzymes based on carbon backbone (RMSD: 0.728
Å). Green color denotes LmTR and blue is for LiTR. Arrows
indicate beta sheets and turns show alpha helices; (b) Ribbon
imaging of LmTR shows FAD binding domain (red), NADPH
binding domain (green) and interface domain (cyan).
Superimposition of the FAD (c), NADPH (d) and interface
domains (e) of the trypanothione reductases from L. infantum
(orange), L. mexicana (red), C. fasciculata (green) and T. cruzi
(blue).
Fig. 3: SOPMA server results for the secondary structure of the model LmTR. J Vector Borne Dis 50, March 2013 42
Overall structure
Secondary structure of TR from L. mexicana was pre-
dicted by SOPMA server. As a result, random coils
(33.2%) and alpha helices (33.6%) are dominant features.
Extended strands and beta turns have found as 24.85 and
8.35% respectively (Fig. 3). Crystal structure of TR from
L. infantum21, C. fasciculata20 and T. cruzi18, 19 were
solved. According to these studies all the TRs share three
domains; FAD binding domain, NADPH binding domain
and interface domain which are responsible in forming
dimer state21 (Fig. 2). Catalytic site comprises redox ac-
tive disulfide bridge (Cys52–Cys57 in L. infantum and
Cys53–Cys58 in T. cruzi) and an active site base (His461)
of the interface domain19, 21. In LmTR redox active resi-
dues,  active site bases are found in the positions Cys52–
Cys57 and His461 like those found in L. infantum TR
and Cys52–Cys57 form a disulfide bond about 2.2 Å dis-
tance (2.05 Å in LiTR) (Fig. 4). FAD domain consists
five stranded parallel beta sheets (7–10, 31–35, 119–124,
155–158 and 322–324), three stranded antiparallel beta
sheets (126–129, 134–138 and 149–152) and four alpha
helices (14–26, 50–78, 92–116 and 335–349). NADPH
domain contains three stranded antiparallel, three paral-
lel beta sheets and two alpha helices. Interface domain
located after the residue 360 to the end of the structure
which contains four stranded antiparallel beta sheets and
one alpha helix. NADPH binding domain residues
(Tyr221, Arg222, Arg228/229, Tyr198, Ile199, Met333,
Ala365 and Glu202/203) found in LiTR and TcTR well-
preserved in the LmTR. These analyses show that the
overall fold of LmTR highly resemble to those of other
TRs’ crystal structures. According to the active site and
pocket prediction results, eight different pockets were
identified by Molsoft ICM and 10 were from CASTp-
computer atlas of surface topography of proteins and 13
were from GHECOM 1.0: Grid-based HECOMi finder.
Results from Molsoft are given in Fig. 4 and Table 1.
Pockets (Number 1 and 4) occupy the area of NADPH
Fig. 4: (a) Disulfide bridge (C52–C57) region of the LiTR; (b) Disulfide bridge (C52–C57) region of the LmTR; (c) Active site residues (C52–
C57 and H461) of the modeled LmTR enzyme; and (d) Predicted ligand binding pockets by icmPocketFinder (Molsoft ICM) for LmTR;
Total enzyme structure was represented as grey and pockets are in orange. 43 Mutlu: Homology modeling of trypanothione reductase
Table 1. Identified volume, area and residue information of possible ligand binding pockets.
Pocket No. Volume (AAA) Area(AA) Pocket residues
1 1565.2 1396.1 I10:^G16,^V34:^L36,^L44,^A46:^A47,^G50:^C52,^V55:^V58,^K60:^K61,^G125:^A128
^R138,^S140:^E141,^Q143,^A159:^W163,^S178,^F182,^Y198:^I199,^F203,^F230,^R287,
^R290,^Q292:^Q295,^I325:^V328,^M333:^A338,^N340,^T357:^D358,^T360:^F367,^P435,^I438:
^Q439,^G442:^I443,^K446
2 324.355 304.9 G66:^A67,^Y69:^M70,^L73:^R74,^R85,^L88:^S90,^G209:^R213"
3 234.547 278.676 F396,^P398:^H401,^K409,^F411,^G431:^S433,^H461:^S464,^E466:^E467
4 224.235 269.759 ^L167,^V194:^I199,^Y221:^R222,^L227:^R228,^S254:^P255,^A284:^R287
5 167.787 216.276 ^S440:^V441,^C444,^M447,^A449,^D453:^F454,^T457,^G459:^V460,^T463,
^A465:^E466,^L468:^C469
6 142.982 171.104 ^G229:^F230,^H359:^V362,^C364,^T374:^T378,^H428
7 129.093 138.48 ^S14,^L17:^E18,^W21,^V53,^Y110,^M113,^T335,^I339
8 116.639 145.139 ^K61,^V64:^T65,^Q68,^F367:^I369,^P371,^S433,^P435:^E436
Residues with bold type indicate active site (C52 and H461) and NADPH binding (Y198, I199, M333, Y221, R222 and R228) residues.
binding site that comprises of Tyr198, Ile199, Met333,
Tyr221, Arg222 and Arg228 residues where pocket 1 and
3 occupy the region of the active site residues (Cys52
and His461) found.
CONCLUSION
Although all Leishmanias share a unique thiol-based
metabolism which is common to all trypanosomatide fam-
ily members, human hosts lack this antioxidant mecha-
nism. Hence, enzymes of thiol-metabolism are subjected
for drug design studies. Trypanothione reductases catalyse
the transfer of electrons from the cofactor of NAPDH to
trypanothione substrate by the action of FAD and cys-
teine disulfides. In this computational modeling study,
3D structure of TR from the L. mexicana was solved for
the first time by using crystal structure coordinates from
LiTR which shares 90% amino acid sequence identity.
Quality of the 3D structure of the model was confirmed
by various web-based programs. Modeled structure of
LmTR showed high similarity with LiTR based on over-
all structural features like domains and folding patterns.
Structure could provide a good model for further struc-
tural-based drug design and docking studies of various
peptide-based inhibitors.
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